Intellegens to speak at ELRIG event
Thomas Bridge from the Intellegens Science Team will present at the Drug Discovery 2023 event organised by the European Laboratory Research & Innovation Group (ELRIG) in Liverpool in October.
Contact us if you’d like to meet us at the event to discuss applications of machine learning in life sciences.
Title: Harnessing AI for R&D in Drug Discovery
Speaker: Thomas Bridge, Machine Learning Engineer, Intellegens
Track: Augmenting R&D with AI (Auditorium 4)
Timing: Wed, 18 Oct, 15:45-16:15
Drug discovery research and development (R&D) entails significant challenges, including cost-intensive experimental screening, lengthy timelines, and complex scale-ups. The integration of Artificial Intelligence (AI) could transform this process. AI algorithms can be used to precisely identify the most promising candidates for both production and efficacy, thereby reducing time and costs. They can also guide experimental programmes, achieving targets with greatly-reduced numbers of experiments. Embracing AI as a valuable ally in drug discovery R&D accelerates innovation, increases success rates, and ultimately brings life-changing medicines to patients more efficiently. However, ensuring AI reliability, interpretability, and ethical usage remains crucial.
This talk delves into AI’s role throughout all R&D stages in drug discovery, exemplified by impactful case studies, including developing novel antimalarial compounds with Optibrium and Open-Source Malaria, and predicting monoclonal antibody production viability with CPI. Leveraging AI empowers researchers to extract meaningful insights from diverse datasets, revolutionizing scientific discovery and fostering innovation. We will discuss how, using the Intellegens machine learning (ML) software, Alchemite™, we were able to handle challenges that often prevent ML being applied to datasets in R&D, including the curse of dimensionality, sparsity and noise.